Adaptive Biotechnologies Q3 net income drops 71% to $2.81 million

PUBT · 18h ago
Adaptive Biotechnologies Q3 net income drops 71% to $2.81 million
  • Adaptive Biotechnologies' third-quarter 2026 net income fell 71% to $2.81 million, while revenue dropped 11% to $83.9 million.
  • MRD revenue climbed 28% to $72.6 million, while clonoSEQ test volume rose 46% to 39,587.
  • NCCN guidelines established a dedicated framework for MRD assessment in multiple myeloma, including annual testing during maintenance.
  • Full-year 2026 MRD revenue guidance increased to $276 million–$286 million; expected operating expenses narrowed to approximately $350 million.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Adaptive Biotechnologies Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611041605PRIMZONEFULLFEED9870444) on November 04, 2026, and is solely responsible for the information contained therein.